New hope for kids with brain cancer? LAM561 trial launches
Disease control
Recruiting now
This study tests an oral drug called LAM561 in children under 18 with advanced brain tumors (like high-grade glioma) or other solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose in up to 18 children, then testing that …
Phase: PHASE1, PHASE2 • Sponsor: Laminar Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC